Thursday , November 23 2017
Home / Resources / Videos / ADA 2017 / Joel Goldsmith Part 4, Emerging Trends In CGM Technologies

Joel Goldsmith Part 4, Emerging Trends In CGM Technologies

In part 4 of this Exclusive Interview, Joel Goldsmith talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about the effectiveness of the new CGM system in the management of diabetes.

Joel Goldsmith is the Senior Director of Digital Platforms at Abbott Diabetes Care where he and his team are focused on designing, developing, and commercializing software-based products and services.

Transcript of this video segment:

Steve Freed — What are the emerging trends within the CGM space that are going to transform diabetes management?

Joel Goldsmith — I think a lot of them revolve around those shifts that I described at the beginning. It starts with this shift from strip to sensor because the data acts as the fuel for everything that’s happening in digital health and a sensor enables that data to be acquired in an effortless way. The second of those two is from proprietary devices to connected consumer electronic products so now that you’re seeing a growing emergence of mobile medical apps running on popular devices, namely smartphones, that smartphone really acts in a couple meaningful ways. One, it’s a common development platform so that software can be developed in advance on a much faster time cycle but those devices tend to have a persistent connection to the Internet and the fact that they’re connected devices that data can be instantly and automatically uploaded to cloud-based services, which is the third major shift. Those cloud-based services act not only as essential data repository as a recording solution, but also as a gateway for that data to be shared with a growing number of apps, devices and other cloud-based services. So, those three things in combination advance the overall opportunity moving from script to sensor.

Steve Freed — The Libre Pro, because it’s blinded, would you say it’s more for the type 2 patient or the type one patient?

Joel Goldsmith — Because it’s used to establish a baseline or to help reveal the root cause of issues that might require a treatment change, it’s really broadly applicable, certainly to any patient who is on insulin and they are the ones that frequently might need to have a treatment adjustment, but we imagine that it could be applicable to anyone that’s been diagnosed with diabetes even eventually possibly as a way of detecting prediabetes.

Return to the main page.